The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 28, 2019

Filed:

Aug. 02, 2016
Applicant:

Astellas Pharma Inc., Chuo-ku, JP;

Inventors:

Takashi Sugane, Tokyo, JP;

Takuya Makino, Tokyo, JP;

Daisuke Yamashita, Tokyo, JP;

Yasuhiro Yonetoku, Tokyo, JP;

Daisuke Tanabe, Tokyo, JP;

Hisashi Mihara, Tokyo, JP;

Norio Asai, Tokyo, JP;

Kazuhiko Osoda, Tokyo, JP;

Takafumi Shimizu, Tokyo, JP;

Hiroyuki Moritomo, Tokyo, JP;

Keizo Sugasawa, Tokyo, JP;

Kyoichi Maeno, Tokyo, JP;

Naomi Hosogai, Tokyo, JP;

Assignee:

Astellas Pharma Inc., Chuo-ku, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/06 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); A61P 13/02 (2006.01); A61P 13/10 (2006.01);
U.S. Cl.
CPC ...
C07D 403/06 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61P 13/02 (2018.01); A61P 13/10 (2018.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 417/14 (2013.01);
Abstract

To provide a compound which can be used as an MCreceptor agonist. The present inventors have investigated MCreceptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MCreceptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.


Find Patent Forward Citations

Loading…